In this article, Evan Lewis, director of the Neurology Centre of Toronto, VP Psychedelic Neurology for Numinus and an expert in cannabis and childhood epilepsy, discusses...
Enveric Biosciences has made advancements with its drug discovery and development progress targeting mental health indications and intellectual property (IP).
Cybin has confirmed that it has received a “may proceed letter” and Investigational New Drug Application (IND) clearance from the U.S.
MAPS PBC is entering into a collaboration that aims to bring its novel therapy for PTSD closer to regulatory evaluation.
Dimensions has launched its new international plant medicine retreat series in Jamaica.
Awakn Life Sciences has filed a Patent Cooperation Treaty (PCT) application for the treatment of behavioural addictions with ketamine and ketamine-assisted psychotherapy.
In recent weeks, much has been made of psychedelic drugs’ potential to redefine mental health treatment.
“Psilocybin products may be unregulated and even illegal in many markets, but producers of psilocybin are more conscious of the consumer than the cannabinoid industry appears...
Freya Masters is a recent graduate from the University of St Andrews where she studied biochemistry.
A Canadian psychedelics company has received approval to move to the top tier of the TSX Venture Exchange market.